Status:
COMPLETED
Impact of AIT on Allergic Rhinitis and Asthma
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergy
Respiratory Disease
Eligibility:
All Genders
Brief Summary
The study will assess the effectiveness of AIT treatment in real clinical practice in Germany.
Detailed Description
Allergic rhinitis (AR) affects 23-30% of the European population and is associated with a major burden on public health. AR and asthma frequently coexist, and may both be caused by allergen exposure. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria for the AIT cohort:
- At least two index-AIT prescriptions during the first FU-year
- At least one confirmed AR diagnosis during the study period
- Continuous enrollment (no gaps in insurance time-defined by days) for 12 months before the index event (in the pre-index period)
- Continuous enrollment (no gaps in insurance time-defined by days) for at least 12 months after the index event (in the post-index period)
- Inclusion Criteria for the Control Cohort:
- \- For the control groups, the same inclusion criteria will apply, with the exception of inclusion criterion 1, i.e. controls have not received AIT before baseline.
- Exclusion Criteria:
- \- AIT prescription 12 months before the index event (in the pre-index period) for the AIT treatment group
Exclusion
Key Trial Info
Start Date :
July 22 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 16 2021
Estimated Enrollment :
92048 Patients enrolled
Trial Details
Trial ID
NCT04125888
Start Date
July 22 2019
End Date
April 16 2021
Last Update
June 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ALK Abelló
Hørsholm, Denmark, DK-2970